AR083786A1 - Compuestos antidiabeticos - Google Patents
Compuestos antidiabeticosInfo
- Publication number
- AR083786A1 AR083786A1 ARP110104150A ARP110104150A AR083786A1 AR 083786 A1 AR083786 A1 AR 083786A1 AR P110104150 A ARP110104150 A AR P110104150A AR P110104150 A ARP110104150 A AR P110104150A AR 083786 A1 AR083786 A1 AR 083786A1
- Authority
- AR
- Argentina
- Prior art keywords
- fgf21
- linker
- covalently linked
- antidiabetic compounds
- diabetes
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000003178 anti-diabetic effect Effects 0.000 title 1
- 239000003472 antidiabetic agent Substances 0.000 title 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 abstract 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 abstract 3
- 229940126864 fibroblast growth factor Drugs 0.000 abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente solicitud proporciona una molécula de FGF21 (factor de crecimiento de fibroblastos) unida covalentemente al sitio de combinación de un anticuerpo mediante un engarce, en la que el engarce está unido covalentemente a la cadena lateral de un resto de unión dentro de FGF21. Se proporcionan diversos usos de los compuestos, incluyendo procedimientos para prevenir o tratar la diabetes o afecciones relacionadas con la diabetes.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41071510P | 2010-11-05 | 2010-11-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR083786A1 true AR083786A1 (es) | 2013-03-20 |
Family
ID=45401106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110104150A AR083786A1 (es) | 2010-11-05 | 2011-11-07 | Compuestos antidiabeticos |
Country Status (18)
Country | Link |
---|---|
US (1) | US8722622B2 (es) |
EP (1) | EP2635309A2 (es) |
JP (1) | JP2014500248A (es) |
KR (1) | KR20130086623A (es) |
CN (1) | CN103282055A (es) |
AR (1) | AR083786A1 (es) |
AU (1) | AU2011324886A1 (es) |
BR (1) | BR112013011172A2 (es) |
CA (1) | CA2815967A1 (es) |
CO (1) | CO6741158A2 (es) |
IL (1) | IL225895A0 (es) |
MX (1) | MX2013005075A (es) |
PE (1) | PE20140260A1 (es) |
RU (1) | RU2013118441A (es) |
SG (1) | SG190082A1 (es) |
TW (1) | TW201233685A (es) |
WO (1) | WO2012059873A2 (es) |
ZA (1) | ZA201303657B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9574002B2 (en) | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
EP3125921B1 (en) | 2014-03-11 | 2020-07-08 | Novartis AG | Fgf21 variants for use in treating hiv-haart induced partial lipodystrophy |
US10328131B2 (en) | 2014-03-13 | 2019-06-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for regulating pancreatic beta cell function using adipsin |
MY198629A (en) | 2014-07-24 | 2023-09-11 | Genentech Inc | Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond |
US11638745B2 (en) | 2015-05-20 | 2023-05-02 | University of Pittsburgh—Of the Commonwealth Cvctom of Hierher Education | Method to improve neurologic outcomes in temperature managed patients |
RU2752530C2 (ru) | 2015-08-03 | 2021-07-29 | Новартис Аг | Способы лечения расстройств, связанных с fgf21 |
US10899844B2 (en) | 2017-02-08 | 2021-01-26 | Novartis Ag | FGF21 mimetic antibodies and uses thereof |
WO2020010117A2 (en) | 2018-07-03 | 2020-01-09 | Bristol-Myers Squibb Company | Fgf21 formulations |
EP3863672A4 (en) * | 2018-10-11 | 2022-06-29 | The Scripps Research Institute | Antibody compounds with reactive arginine and related antibody drug conjugates |
AR122359A1 (es) * | 2020-01-08 | 2022-09-07 | Bristol Myers Squibb Co | Formulaciones de fgf-21 conjugado |
CN113728013B (zh) | 2020-01-11 | 2022-06-14 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
CA3217236A1 (en) * | 2021-04-30 | 2022-11-03 | Innovent Biologics (Suzhou) Co. Ltd. | Oxm3 storage agent, oxm3 preparation, and preparation method |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5733757A (en) | 1995-12-15 | 1998-03-31 | The Scripps Research Institute | Aldolase catalytic antibody |
US6326176B1 (en) | 1997-12-18 | 2001-12-04 | The Scripps Research Institute | Aldol condensations by catalytic antibodies |
US7408047B1 (en) | 1999-09-07 | 2008-08-05 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
US6294374B1 (en) | 1999-10-08 | 2001-09-25 | The Scripps Research Institute | Use of catalytic antibodies for synthesizing epothilone |
EP1228087B1 (en) | 1999-10-08 | 2010-06-09 | The Scripps Research Institute | Antibody catalysis of enantio- and diastereo-selective aldol reactions |
US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
EP1443963B1 (en) | 2001-10-22 | 2014-05-21 | The Scripps Research Institute | Antibody targeting compounds |
WO2003059270A2 (en) | 2002-01-15 | 2003-07-24 | Eli Lilly And Company | Method for reducing morbidity and mortality in critically ill patients |
ES2298785T3 (es) * | 2003-06-12 | 2008-05-16 | Eli Lilly And Company | Proteinas de fusion. |
EA200601121A1 (ru) | 2003-12-10 | 2006-10-27 | Эли Лилли Энд Компани | Мутеины фактора роста фибробластов 21 |
WO2005072769A1 (en) | 2004-01-26 | 2005-08-11 | Eli Lilly And Company | Use of fgf-21 and thiazolidinedione for treating type 2 diabetes |
EP1735340A2 (en) * | 2004-03-17 | 2006-12-27 | Eli Lilly And Company | Glycol linked fgf-21 compounds |
US7576190B2 (en) | 2004-05-13 | 2009-08-18 | Eli Lilly And Company | FGF-21 fusion proteins |
EP2161281A1 (en) | 2004-09-02 | 2010-03-10 | Eli Lilly & Company | Muteins of fibroblast growth factor 21 |
US7622445B2 (en) | 2004-09-02 | 2009-11-24 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
SI2586456T1 (sl) | 2004-10-29 | 2016-05-31 | Ratiopharm Gmbh | Preoblikovanje in glikopegliacija fibroblastnega rastnega faktorja (FGF) |
US7655627B2 (en) | 2004-12-14 | 2010-02-02 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
JP2008528487A (ja) | 2005-01-21 | 2008-07-31 | イーライ リリー アンド カンパニー | 心臓血管疾患を治療する方法 |
CN101287485A (zh) * | 2005-03-03 | 2008-10-15 | 爱尔兰考夫克斯科技有限公司 | 抗血管生成化合物 |
US20080152660A1 (en) | 2005-03-03 | 2008-06-26 | Bradshaw Curt W | Anti-Angiogenic Compounds |
KR20120043028A (ko) | 2006-11-10 | 2012-05-03 | 씨오브이엑스 테크놀로지스 아일랜드 리미티드 | 혈관 신생 억제 화합물 |
US20090098130A1 (en) * | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
BRPI0809583B1 (pt) | 2007-03-30 | 2022-02-22 | Ambrx, Inc | Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo |
US8293714B2 (en) * | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
JOP20190083A1 (ar) * | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
WO2010065439A1 (en) * | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants of fibroblast growth factor 21 |
US20120052069A1 (en) * | 2009-05-05 | 2012-03-01 | Amgen Inc | Fgf21 mutants and uses thereof |
CA2777717C (en) * | 2009-10-15 | 2021-05-25 | Genentech, Inc. | Chimeric fibroblast growth factors with altered receptor specificity |
KR20130050966A (ko) * | 2010-07-12 | 2013-05-16 | 씨오브이엑스 테크놀로지스 아일랜드 리미티드 | 다기능적 항체 접합체 |
-
2011
- 2011-11-02 CA CA2815967A patent/CA2815967A1/en not_active Abandoned
- 2011-11-02 SG SG2013033378A patent/SG190082A1/en unknown
- 2011-11-02 KR KR1020137014378A patent/KR20130086623A/ko not_active Application Discontinuation
- 2011-11-02 JP JP2013537240A patent/JP2014500248A/ja active Pending
- 2011-11-02 BR BR112013011172A patent/BR112013011172A2/pt not_active Application Discontinuation
- 2011-11-02 AU AU2011324886A patent/AU2011324886A1/en not_active Abandoned
- 2011-11-02 RU RU2013118441/15A patent/RU2013118441A/ru not_active Application Discontinuation
- 2011-11-02 EP EP11799823.7A patent/EP2635309A2/en not_active Withdrawn
- 2011-11-02 CN CN2011800641240A patent/CN103282055A/zh active Pending
- 2011-11-02 MX MX2013005075A patent/MX2013005075A/es unknown
- 2011-11-02 WO PCT/IB2011/054874 patent/WO2012059873A2/en active Application Filing
- 2011-11-02 PE PE2013000931A patent/PE20140260A1/es not_active Application Discontinuation
- 2011-11-03 TW TW100140134A patent/TW201233685A/zh unknown
- 2011-11-04 US US13/289,533 patent/US8722622B2/en not_active Expired - Fee Related
- 2011-11-07 AR ARP110104150A patent/AR083786A1/es not_active Application Discontinuation
-
2013
- 2013-04-22 IL IL225895A patent/IL225895A0/en unknown
- 2013-05-03 CO CO13111846A patent/CO6741158A2/es unknown
- 2013-05-20 ZA ZA2013/03657A patent/ZA201303657B/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG190082A1 (en) | 2013-06-28 |
CO6741158A2 (es) | 2013-08-30 |
JP2014500248A (ja) | 2014-01-09 |
RU2013118441A (ru) | 2014-12-10 |
CA2815967A1 (en) | 2012-05-10 |
US8722622B2 (en) | 2014-05-13 |
US20120282279A1 (en) | 2012-11-08 |
WO2012059873A3 (en) | 2012-06-28 |
WO2012059873A2 (en) | 2012-05-10 |
TW201233685A (en) | 2012-08-16 |
AU2011324886A1 (en) | 2013-05-23 |
BR112013011172A2 (pt) | 2017-06-06 |
IL225895A0 (en) | 2013-06-27 |
ZA201303657B (en) | 2014-04-30 |
EP2635309A2 (en) | 2013-09-11 |
CN103282055A (zh) | 2013-09-04 |
PE20140260A1 (es) | 2014-03-19 |
KR20130086623A (ko) | 2013-08-02 |
MX2013005075A (es) | 2013-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR083786A1 (es) | Compuestos antidiabeticos | |
CU20110052A7 (es) | Compuestos orgánicos | |
CR11241A (es) | Compuestos de pirazol y su uso como inhibidores de raf | |
ECSP12011799A (es) | Compuestos de espiropiperidina y uso farmacéutico de los mismos | |
EA201270242A1 (ru) | Антипролиферативные соединения, их конъюгаты, способы их получения и их применение | |
ECSP11011183A (es) | Compuestos orgánicos | |
ECSP11011184A (es) | Compuestos orgánicos | |
CO6430459A2 (es) | Derivados de prolina como inhibidores de catepsina | |
GT201000023A (es) | Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met. | |
UA111161C2 (uk) | Похідна фталазинонкетону, спосіб її одержання та її фармацевтичне застосування | |
ECSP10010582A (es) | Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer | |
CO6620055A2 (es) | Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos | |
GT200900095A (es) | Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas. | |
CO6321282A2 (es) | Derivados de piperidinilindol como inhibidores de aldosterona sintasa | |
EA201490095A1 (ru) | Новые производные майтанзиноида с пептидным линкером и их конъюгаты | |
GT200800242A (es) | Derivados biciclicos como inhibidores de cetp | |
NI200900149A (es) | COMPUESTOS TRICÍCLICOS, COMPOSICIONES, Y PROCEDIMIENTOS. Caso: PC33715A | |
CL2011000134A1 (es) | Compuestos derivados de aminofenoxiindazoles, inhibidores de c-met; composicion farmaceutica que comprende a estos compuestos; y su uso para tratar el cancer. | |
HN2010001920A (es) | Dihidropirazolonas sustituidas como inhibidores de hif- propil-4-hidroxilasa | |
CR20110413A (es) | Uso como bactericidas de análogos ácidos heteroaromáticos que contienen azufre | |
UY32153A (es) | Inhibidores de piridomidinona de pi13ka(alfa) y mtor | |
EA200900090A1 (ru) | Бензиламины, способ их получения и их применение в качестве противовоспалительных средств | |
BR112012006172A2 (pt) | derivados de alqueno oxindol e seus usos para o tratamento de obesidade, diabetes e hiperlipidemia | |
GT200700074A (es) | Fungicidas | |
UA107455C2 (uk) | Похідні індолу як протиракові агенти |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |